Trial Profile
A single arm confirmatory study of pembrolizumab in patients with previously untreated advanced sarcomatoid carcinoma of the lung
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Lung cancer
- Focus Therapeutic Use
- 21 Sep 2021 Status changed from active, no longer recruiting to discontinued.
- 06 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2019 Status changed from not yet recruiting to recruiting.